2019 AGM Materials
For Patients/Physicians
Lupus Nephritis (LN)
Corporate Governance and Documents
Governance and Documents
Aurinia to Participate in November Investor Conferences
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.
Wednesday, November 14, 2018, Aurinia will present a company overview at the Jefferies 2018 London Healthcare Conference in London, UK at 10:00am GMT. The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of will also be archived on the site following the event.
Tuesday, November 27, 2018, Aurinia will participate in One-on-One Meetings at the Evercore ISI HealthCONx Conference in Boston, MA.
About Aurinia
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.
We seek safe harbor.
Celia Economides
VP, Corporate & Public Affairs
IR@auriniapharma.com
Christopher Hippolyte, 212-364-0458
Christopher.hippolyte@inventivhealth.com
Source: Aurinia Pharmaceuticals Inc.
Released November 9, 2018
Stay informed and receive company updates straight to your inbox
© 2019 Aurinia Pharmaceuticals Inc. All Rights Reserved.
Privacy Statement Terms of Use Disclaimer Sitemap